RESUMEN
Clinical and experimental studies have revealed that salbupart, a beta-mimetic agent, administered in a dose of 0.14 mg/kg (the maximal therapeutic dose) markedly inhibited the spontaneous and oxytocin-induced uterine contractility, caused no embryotoxic or teratogenic effects, and did not influence fetal growth and development. The efficacy of salbupart tocolytic therapy was estimated as 75%. Blood plasma cAMP levels normalized in the pregnant women over the course of therapy. Clinical and experimental results recommend salbupart for pregnancy protecting therapy in cases with threatened spontaneous abortions.
Asunto(s)
Amenaza de Aborto/tratamiento farmacológico , Albuterol/uso terapéutico , Tocolíticos/uso terapéutico , Amenaza de Aborto/fisiopatología , Albuterol/toxicidad , Animales , Evaluación de Medicamentos , Evaluación Preclínica de Medicamentos , Desarrollo Embrionario y Fetal/efectos de los fármacos , Femenino , Fenoterol/uso terapéutico , Humanos , Embarazo , Ratas , Tocolíticos/toxicidad , Contracción Uterina/efectos de los fármacosRESUMEN
This paper reports results of clinical and experimental studies which sought to validate endonasal laser treatment for prevention of dysfunctional labor in late toxemia. Electrophysiologic and histochemical studies showed stimulating effects of the helium-neon laser treatment on function of large cell hypothalamic nuclei and uterine contractility. Clinical efficiency of this treatment was seen as a lower incidence of dysfunctional labor and cesarean section.
Asunto(s)
Terapia por Láser , Preeclampsia/fisiopatología , Atención Prenatal/métodos , Contracción Uterina/efectos de la radiación , Inercia Uterina/prevención & control , Animales , Modelos Animales de Enfermedad , Femenino , Helio , Humanos , Neón , Preeclampsia/complicaciones , Embarazo , Ratas , Contracción Uterina/fisiología , Inercia Uterina/etiología , Inercia Uterina/terapiaAsunto(s)
Animales Recién Nacidos/fisiología , Peso al Nacer/efectos de la radiación , Desarrollo Embrionario y Fetal/efectos de la radiación , Isquemia/radioterapia , Microondas/uso terapéutico , Actividad Motora/efectos de la radiación , Enfermedades Placentarias/radioterapia , Placenta/irrigación sanguínea , Insuficiencia Placentaria/radioterapia , Animales , Desarrollo Embrionario y Fetal/fisiología , Femenino , Isquemia/complicaciones , Isquemia/fisiopatología , Masculino , Intercambio Materno-Fetal , Actividad Motora/fisiología , Insuficiencia Placentaria/etiología , Insuficiencia Placentaria/fisiopatología , Embarazo , RatasRESUMEN
In experiments on rats it was found that fenibut (50 mg/kg, 1/20 of LD50) during a single and repeated administration in the fetus period of pregnancy does not exert any negative effect on the maternal organism, the growth and development of the fetus. Seduxen administered in a dose of 50 mg/kg (1/80 of LD50) alone and in combination with fenibut was shown to decrease the female body weight gain and to disturb the fetus development. Following a single administration on the 17th day of pregnancy, the effect was poorly pronounced.